This morning the Northwest Biotherapeutics (OTCMKTS:NWBO) stock has jumped by 4% after the company made an announcement with regards to its manufacturing facility in the United Kingdom and also provided updates about a Phase III trial.
The company announced this morning that it has submitted an application to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for certifying its manufacturing plant located at Sawston. Northwest is best known for having developed DCVax, which is meant for providing customized immune therapies for those suffering from cancer.
The application form Northwest has been submitted after it had made preparations for this for more than two years. Additionally, the company had continued with its efforts with regards to the Sawston facility despite the coronavirus-related restrictions last year. Earlier this year in March, it had been reported that Phase I of physical build-out at the facility had been completed. It is an important milestone for Northwest and could prove to be a boost for the stock as well.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life